Gene Therapy Approaches to Replace or Restore Dystrophin PF-06939926 – Kasia Lobello, MD (Pfizer, Inc.) RGX-202 – Jahannaz Dastgir, DO (REGENXBIO) scAAV9.U7-ACCA – Kevin Flanigan, MD (Nationwide Children’s Hospital) SGT-001 – Carl Morris, PhD (Solid Biosciences) SRP-9001 – Teji Singh, MD (Sarepta Therapeutics) 2022 PPMD Annual Conference,Conferences & Meetings 2 years ago You may also like 7:11 Epirium Bio 4 years ago Conferences & Meetings,In the Pipeline: Downstream Targets 18:36 Sarepta Therapeutics (RNA Targeted Therapies) 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 11:46 NS Pharma 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 11:20 PTC Therapeutics (Ataluren) 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 15:10 Daiichi-Sankyo 4 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 20:43 ReveraGen BioPharma 4 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 12:20 Catabasis 4 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 11:23 Antisense Therapeutics 4 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation «1…1920212223…25»Page 21 of 25